Attendee search 

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.